Protocol Ledger

NCT04770753 · Phase III · ACTIVE NOT RECRUITING

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

Interventional Phase III clinical trial protocol NCT04770753 sponsored by Agios Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-20 Enrollment: 194 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04770753
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)194 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04770753
Protocol FieldVerified Registry Value
NCT IdentifierNCT04770753
Consolidated Lead SponsorAgios Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment194 participants (ACTUAL)
Registered Start Date2021-12-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI